Literature DB >> 32611576

T-cell and NK-cell neoplasms of the gastrointestinal tract - recurrent themes, but clinical and biological distinctions exist.

Elaine S Jaffe1.   

Abstract

Entities:  

Year:  2020        PMID: 32611576      PMCID: PMC7327655          DOI: 10.3324/haematol.2020.252924

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 2.  Spontaneously relapsing clonal, mucosal cytotoxic T-cell lymphoproliferative disorder: case report and review of the literature.

Authors:  E A Ranheim; C Jones; J L Zehnder; R Warnke; A Yuen
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

3.  Indolent T-cell lymphoproliferative disease of the gastrointestinal tract.

Authors:  Anamarija M Perry; Roger A Warnke; Qinglong Hu; Philippe Gaulard; Christiane Copie-Bergman; Serhan Alkan; Huan-You Wang; Jason X Cheng; Chris M Bacon; Jan Delabie; Erik Ranheim; Can Kucuk; Xiaozhou Hu; Dennis D Weisenburger; Elaine S Jaffe; Wing C Chan
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

4.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.

Authors:  Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami
Journal:  Nat Med       Date:  2005-05-15       Impact factor: 53.440

5.  Malignant histiocytosis of the intestine: a T-cell lymphoma.

Authors:  P G Isaacson; N T O'Connor; J Spencer; D H Bevan; C E Connolly; N Kirkham; D J Pollock; J S Wainscoat; H Stein; D Y Mason
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

6.  Relapsing oral and colonic ulcers with monoclonal T-cell infiltration. A low grade mucosal T-lymphoproliferative disease of the digestive tract.

Authors:  N Egawa; M Fukayama; K Kawaguchi; T Hishima; Y Hayashi; N Funata; T Ibuka; M Koike; H Miyashita; T Tajima
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

Review 7.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.

Authors:  Geoffrey Shouse; Liana Nikolaenko
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

8.  Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.

Authors:  Ayush Sharma; Naoki Oishi; Rebecca L Boddicker; Guangzhen Hu; Hailey K Benson; Rhett P Ketterling; Patricia T Greipp; Darlene L Knutson; Sara M Kloft-Nelson; Rong He; Bruce W Eckloff; Jin Jen; Asha A Nair; Jaime I Davila; Surendra Dasari; Konstantinos N Lazaridis; N Nora Bennani; Tsung-Teh Wu; Grzegorz S Nowakowski; Joseph A Murray; Andrew L Feldman
Journal:  Blood       Date:  2018-03-28       Impact factor: 25.476

9.  Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.

Authors:  Annalisa Roberti; Maria Pamela Dobay; Bettina Bisig; David Vallois; Cloé Boéchat; Evripidis Lanitis; Brigitte Bouchindhomme; Marie-Cécile Parrens; Céline Bossard; Leticia Quintanilla-Martinez; Edoardo Missiaglia; Philippe Gaulard; Laurence de Leval
Journal:  Nat Commun       Date:  2016-09-07       Impact factor: 14.919

10.  Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features.

Authors:  Elizabeth Margolskee; Vaidehi Jobanputra; Suzanne K Lewis; Bachir Alobeid; Peter H R Green; Govind Bhagat
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.